03 agosto 2016

Grifols . The results of phase I clinical trial of the Araclon Biotech Alzheimer's vaccine support its continuation .

-- The conclusions of the trial were presented at the Alzheimer's Association International Conference in Toronto. The compound ABvac40, designed to combat Alzheimer's disease at its initial stage, has demonstrated a good safety and tolerability profile.

-- This phase I blinded study did not evaluate the efficacy of the treatment. However, ABvac40 produced an immune response in more than 87% of patients who received the product during the trial.

BARCELONA, Aug. 1, 2016 /PRNewswire/ -- 

Araclon Biotech, in which Grifols is the majority shareholder, has presented the results of the phase I clinical trial for its active immunotherapy against Alzheimer's disease (ABvac40) at the Alzheimer's Association International Conference (AAIC 2016), held in Toronto (Canada) from July 24 to 28, and organized by the American Alzheimer's Association.

The conclusions of this phase I blinded study were satisfactory and support the continuation of the development of ABvac40. The researchers confirmed that treatment with ABvac40 has a good safety and tolerability profile, and the company has started planning a clinical phase II.